📖 Approx. 12 min
When considering M&A for a medical institution, two primary transaction structures typically emerge: “stock transfer” and “business transfer.” However, due to industry-specific legal regulations, types of medical corporations, and complex tax implications, decision-making requires far more care and nuance than in standard corporate M&A. From the perspectives of both buyers and sellers, this article provides an in-depth explanation of the characteristics, advantages, disadvantages, and critical practical considerations of each scheme to help you build the optimal M&A strategy for your institution.
Fundamentals and Characteristics of Stock Transfer (Transfer of Equity Interest) in Medical M&A
In medical M&A, a “stock transfer” generally refers to a “transfer of equity interest” (ownership share) in a medical corporation. Under this structure, an equity holder (member) of a medical corporation with equity interest (an incorporated medical association) transfers their ownership interest to a third party, thereby transferring management control. In the case of a clinic organized as a joint-stock company (kabushiki kaisha), it literally entails a transfer of corporate shares.
The primary advantage of this structure is the continuity of the corporate entity. Consequently, the medical institution’s establishment license, designation as an insured medical institution, various administrative approvals, and reimbursement facility standards are, in principle, preserved and inherited intact. Employment contracts with staff and contracts with business partners generally continue without substantial administrative procedures, facilitating a relatively seamless post-deal transition. From a capital gains tax perspective, individual seller equity holders are subject to separate taxation on the transfer gain (income tax and resident tax), avoiding corporate income taxes.
Conversely, the main drawback is that the buyer inherits the corporate entity as a whole, along with any off-balance-sheet liabilities, contingent liabilities, or past legal risks borne by the seller’s medical corporation. Therefore, the buyer must conduct comprehensive due diligence across financial, legal, tax, and labor matters to thoroughly identify potential liabilities. Furthermore, in the case of a medical corporation without equity interest (such as a fund-funded medical corporation / kikin-kyoshutsu-gata), contributed funds merely represent a right to claim a refund and are not property rights subject to transfer. As a result, a stock-transfer equivalent structure cannot be applied, requiring parties to explore a scheme functionally closer to a business transfer.
[Key Takeaway] Differences: Medical Corporations With vs. Without Equity Interest
- Medical Corporation with Equity Interest: Proprietary equity interests exist, and ownership/management control shifts through their transfer. M&A transactions adopt a scheme equivalent to a stock transfer.
- Medical Corporation without Equity Interest: No equity interest exists; contributed funds merely constitute a right of claim for reimbursement. A business transfer scheme serves as the primary option, and the refund of contributed funds does not directly correspond to M&A purchase consideration.
Fundamentals and Characteristics of Business Transfer in Medical M&A
A “business transfer” is an asset purchase structure where a buyer selectively acquires designated assets (medical equipment, real estate, patient records, goodwill, etc.) and specific liabilities comprising all or part of a medical corporation’s operations, or the entire business of a sole proprietorship clinic. For successions involving private, non-corporate clinics, a business transfer is the sole available option.
The primary advantage of a business transfer is that the buyer can strictly delineate the scope of acquired assets and assumed liabilities. This significantly reduces the risk of inheriting unintended burdens, such as off-balance-sheet debts, contingent liabilities, or past legal disputes associated with the selling entity. Additionally, the buyer can acquire only the assets aligned with its strategy, streamlining reorganization and operational efficiency. For tax purposes, the buyer can depreciate the acquired assets and, in many cases, amortize goodwill (excess earning power) as a deductible business expense over time.
On the other hand, the disadvantage lies in the complexity and breadth of administrative procedures. In a business transfer, the buyer must submit brand-new applications for an establishment license under the Medical Care Act and for designation as an insured medical institution. Consequently, facility standards under the medical fee schedule often require reapplication and reassessment, potentially leading to temporary interruptions or setbacks in billing specific reimbursements. Moreover, existing employment agreements with the seller terminate in principle, requiring the buyer to execute new employment contracts with staff. Commercial agreements with vendors must also be renegotiated and re-executed individually, demanding considerable time and administrative effort. Particularly amid regional healthcare vision initiatives, transfers involving hospital beds may be subject to rigorous scrutiny regarding bed function modifications and alignment with regional healthcare plans.
- Reapplication for Establishment License and Insured Institution Designation: The buyer must submit new applications to the relevant prefectural government and Regional Bureau of Health and Welfare.
- Re-acquisition of Facility Standards: When the operating entity changes, reimbursement-related facility standards generally require reapplication and reassessment.
- Re-employment of Staff: Employment contracts with the seller terminate in principle, requiring the execution of new employment agreements between the buyer and personnel.
- Re-execution of Existing Contracts: Key agreements—such as those with pharmaceutical wholesalers, medical device manufacturers, and facility leaseholders—must be executed anew by the buyer.
- Regulatory Licensing: Approvals outside the Medical Care Act, such as those governed by the Pharmaceuticals and Medical Devices Act or the Long-Term Care Insurance Act, may also need to be reacquired.
Correlation Between Medical Corporation Type and M&A Scheme Selection
In medical M&A, the legal classification of the medical corporation heavily dictates the feasibility of deal structures. Medical corporations in Japan are broadly classified into “medical corporations with equity interest” and “medical corporations without equity interest,” each differing substantially in how transferable property is defined.
Medical Corporations with Equity Interest (Traditional Incorporated Associations)
In this entity type, contributors hold proprietary rights known as “equity interests” proportional to their capital contributions. In an M&A context, transferring these equity interests functions as a share purchase equivalent. The corporate legal entity remains intact, while management control shifts through changes to the board of directors and corporate membership. Because licenses, permits, and facility standards carry over in principle, this scheme is often attractive to both sellers and buyers due to procedural simplicity. However, new medical corporations with equity interest have not been permitted since April 2007; only entities established prior to that date retain equity interests.
Medical Corporations without Equity Interest (Fund-Funded Corporations, Foundations, etc.)
Medical corporations without equity interest do not issue proprietary equity rights. In fund-funded corporations (kikin-kyoshutsu-gata), contributed capital constitutes only a “claim for reimbursement” and cannot be transferred as an asset. Therefore, a stock-transfer equivalent structure cannot be used to acquire the corporation itself. Instead, the primary avenue is a “business transfer,” in which the buyer acquires the operating assets and operations. Under this route, the buyer must apply anew for licenses and insurance designations, bearing the procedural complexities noted earlier.
Private / Sole Proprietorship Clinics
Because private clinics operated by individual physicians lack independent corporate personhood, a “business transfer” is the only viable M&A structure. The founding physician transfers the operational assets, and the successor must obtain fresh establishment approvals and insurance provider designations.
Because the legal classification of an entity significantly limits structural choices, accurately confirming the entity type of the target medical institution during early-stage exploratory discussions is essential.
| Medical Institution Type | Primary M&A Scheme | Corporate Continuity | Succession of Licenses & Standards |
|---|---|---|---|
| Medical Corporation with Equity Interest | Transfer of equity interest (equivalent to stock transfer) | Maintained | Carried over in principle |
| Medical Corporation without Equity Interest | Business transfer | Buyer establishes new entity/facility | Reapplication & reassessment required |
| Private Clinic (Sole Proprietorship) | Business transfer | Buyer establishes new entity/facility | Reapplication & reassessment required |
Tax Treatment and Capital Gains Comparison
Choosing between a stock transfer and a business transfer has profound tax consequences for both parties. Healthcare M&A involves unique nuances, including industry-specific tax exemptions, requiring specialized tax expertise.
In a Stock Transfer (Transfer of Equity Interest)
The individual seller is subject to capital gains tax on the net proceeds from the transfer. In Japan, this is generally taxed under separate taxation at a flat rate of approximately 20.315% (15.315% national income tax, 5% local resident tax). Corporate tax does not apply to this transaction. From the buyer’s standpoint, the purchase price becomes the acquisition book value of the equity interest and cannot be depreciated. Because the medical corporation’s entity continues uninterrupted, the institutional enterprise tax exemption for core healthcare operations remains intact. However, if the corporation operates ancillary revenue-generating businesses, corporate enterprise tax applies to that portion.
In a Business Transfer
If the seller is a corporate entity, the gain on the transfer is recorded as corporate taxable income, subject to standard corporate income tax, corporate inhabitant tax, and corporate enterprise tax, resulting in an effective tax rate of roughly 30% to 35%. Additionally, business asset sales are subject to consumption tax (excluding non-taxable assets like land or securities). For the buyer, acquired tangible assets (medical equipment, buildings, etc.) can be depreciated. Furthermore, goodwill (purchased excess earning capacity) included in the acquisition price can typically be amortized over 5 years as a deductible expense under tax regulations, offering valuable tax shielding. However, because this constitutes a new establishment, enterprise tax exemptions must be evaluated based on the buyer’s legal form and operational scope.
The tax-related cash flows are illustrated below:
Tax outcomes vary widely depending on deal size, the seller’s legal structure, and the buyer’s accounting posture. Prior to execution, engaging a certified tax accountant or specialized advisor to perform comprehensive tax modeling is imperative.
Practical Considerations: Licenses, Facility Standards, and Contract Succession
The chosen transaction structure directly affects the licensing timeline, the retention of reimbursement facility standards, and the process of contract succession.
Under a Stock Transfer (Transfer of Equity Interest)
Because the medical corporation retains its legal identity, its Medical Care Act establishment permit and designation as an insured medical institution are preserved in principle. While notifications regarding director and representative changes must be filed, new applications are unnecessary. Consequently, reimbursement facility standards remain essentially secure, minimizing post-closing disruption to clinical billing. Similarly, employment agreements and third-party contracts (pharmaceutical supply, equipment leases, real estate) continue automatically without individual novation. Nonetheless, advisors must review existing contracts beforehand to identify any “change of control” clauses that could trigger termination rights.
Under a Business Transfer
Because the buyer acts as a newly establishing entity, it must obtain fresh approvals for clinic/hospital establishment and health insurance designation. Regulatory review is stringent, evaluating applicant credentials, physical structural compliance, and staffing quotas. Where inpatient bed transfers are involved amid regional healthcare restructuring, regulatory alignment with local healthcare delivery plans can significantly lengthen the approval process. Furthermore, reimbursement facility standards must be reapplied for and reassessed, risking interim revenue loss. For specialized institutions—such as regional medical support hospitals or advanced treatment facilities—recertification can be remarkably time-consuming and costly. Employment contracts and vendor relationships must also be formally re-executed by the buyer. While this offers an opportunity to optimize commercial terms, it can present retention challenges for staff and supply chain continuity.
[Checklist] Key Procedures Demanding Attention in Business Transfers
- ✅ Medical Care Act Establishment License (New application)
- ✅ Insured Medical Institution Designation (New application)
- ✅ Reapplication and reassessment of reimbursement facility standards
- ✅ Execution of new employment agreements with transferring staff
- ✅ Re-execution of key vendor, lease, and supplier contracts
- ✅ Articles of Incorporation amendment approvals (in partial carve-outs)
- ✅ Long-Term Care Insurance Provider Designation (if nursing/care services are integrated)
Because these procedural hurdles directly dictate the closing schedule and deal risk, rigorous pre-deal planning with experienced healthcare transaction advisors is vital.
Key Factors Dictating Scheme Selection
Determining whether to pursue a stock transfer (equity transfer) or a business transfer requires a balanced evaluation of stakeholder priorities, institutional attributes, and the regulatory environment.
1. Seller Priorities
Sellers typically prioritize maximizing net after-tax proceeds, procedural simplicity, and job security for their staff. When minimizing tax burden is paramount, a stock transfer is frequently preferred. However, if the seller wishes to retain or liquidate specific non-core assets while divesting clinical operations, or clean up unresolved corporate liabilities, a business transfer may be negotiated. Preserving staff employment generally proceeds more seamlessly under a stock transfer.
2. Buyer Priorities
Buyers focus on risk mitigation, strategic footprint growth, and smooth post-merger integration. When buyers are determined to eliminate off-balance-sheet or contingent liabilities, they strongly favor business transfers. Business transfers are also suitable when acquiring only target divisions or integrating operations into an existing entity. Conversely, if preserving existing high-tier facility standards, licenses, and local brand equity is crucial, a stock transfer is the superior mechanism.
3. Legal Entity Classification
As discussed, medical corporations with equity interest permit equity transfers, whereas corporations without equity interest and sole proprietorships require a business transfer structure. The target’s legal entity type remains the primary structural determinant.
4. Presence and Scale of Contingent / Off-Balance-Sheet Liabilities
If substantial unrecorded liabilities, unpaid overtime claims, or pending malpractice risks are uncovered, buyers typically insist on a business transfer to shield against corporate succession liability. In a stock transfer, due diligence findings will either trigger substantial valuation adjustments, indemnity protections, or a restructuring into an asset deal.
5. Complexity of Licensing and Facility Standard Succession
When the target facility holds complex, high-tier accreditation standards or bed allocation approvals that are difficult to re-obtain, re-applying through a business transfer poses operational uncertainty and potential revenue gaps. In such cases, preserving the corporate entity through a stock transfer represents the most practical pathway. Early engagement with regulatory authorities is critical when regional bed allocation adjustments are involved.
Weighing these variables holistically to reach a mutually satisfactory structure is key to transaction success. Broad valuation benchmarks or standard rules of thumb must be adapted to each institution’s specific profile.
[Summary] Core Criteria for Scheme Selection
- Medical Corporation Type: Whether equity interests exist is decisive.
- Risk Tolerance: Ring-fencing liabilities vs. inheriting the corporate entity in full.
- Procedural Complexity: Administrative burden and time required to re-obtain licenses.
- Tax Implications: Net tax exposure for both buyer and seller.
- Post-M&A Operating Strategy: Seamless continuation vs. structural integration into a wider group.
Healthcare M&A demands specialized regulatory insight and practical industry experience distinct from general corporate finance. The optimal choice between a stock transfer and a business transfer varies widely according to your facility’s operational reality and future goals. At M&A Medical, our dedicated healthcare transaction specialists listen closely to your objectives, guiding you from structural selection through to flawless closing. Please feel free to contact us for an initial consultation.
Consult M&A Medical for Healthcare Succession Support
M&A Medical is a specialized advisory practice dedicated to medical institution M&A and business succession. As a registered M&A support organization certified by the Small and Medium Enterprise Agency, we support both clinic/hospital divestitures addressing succession challenges and strategic healthcare acquisitions on a success-fee basis.
- Free initial consultation and preliminary valuation
- Zero upfront retainer and monthly fees (success-fee only)
- Strict confidentiality (executed under formal NDA)
- Nationwide coverage across all 47 prefectures and all medical specialties
Whether you wish to assess current market valuation, lack an identified successor, or are considering joining a hospital group, we encourage you to consult us early in your exploratory process.